Hemostemix Inc., a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions in Canada. It develops cell therapy products from the patient's own blood, a relatively non-invasive source of therapeutic cells. The company's lead product is ACP-01, which is in Phase II clinical trial for the treatment of critical limb ischemia. It is also developing various types of cells products, such as synergetic cell precursors, myocardial cell precursors, and neural cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-403-3409207
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Hemostemix (CVE:HEM) Frequently Asked Questions
What is Hemostemix's stock symbol?
Hemostemix trades on the Canadian Venture Exchange (CVE) under the ticker symbol "HEM."
Has Hemostemix been receiving favorable news coverage?
News stories about HEM stock have been trending somewhat negative recently, InfoTrie Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Hemostemix earned a media sentiment score of -1.1 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near term.
Who are some of Hemostemix's key competitors?
Some companies that are related to Hemostemix include CEL-SCI (CVM), Botanix Pharmaceuticals (BOT), IntelGenx Technologies (IGX), Promis Neurosciences (PMN), Orgenesis (ORGS), Tissue Regenix Group (TRX), Ergomed (ERGO), Protalix Biotherapeutics (PLX), OptiBiotix Health (OPTI), Pediapharm (PDP), Antibe Therapeutics (ATE), Imugene (IMU), Verona Pharma (VRP), Ampio Pharmaceuticals (AMPE) and Actinium Pharmaceuticals (ATNM).
What other stocks do shareholders of Hemostemix own?
Who are Hemostemix's key executives?
Hemostemix's management team includes the folowing people:
- Mr. Kyle Makofka, Pres & CEO
- Dr. Ravi Jain Ph.D., Chief Scientific Officer
- Ms. Kristin Gulka CPA, CA, Chief Financial Officer
- Ms. Eilat Bain, Director of Operations
How do I buy shares of Hemostemix?
Shares of HEM and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Hemostemix's stock price today?
One share of HEM stock can currently be purchased for approximately C$0.08.
How big of a company is Hemostemix?
Hemostemix has a market capitalization of C$22.56 million.
What is Hemostemix's official website?
How can I contact Hemostemix?
Hemostemix's mailing address is Bay 1, PO Box 10, BLACKFALDS, AB T0M 0J0, Canada. The biotechnology company can be reached via phone at +1-403-3409207.
MarketBeat Community Rating for Hemostemix (CVE HEM)
MarketBeat's community ratings are surveys of what our community members think about Hemostemix and other stocks. Vote "Outperform" if you believe HEM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HEM will underperform the S&P 500 over the long term. You may vote once every thirty days.
